Formulation factors affecting the release of ezetimibe from different liquisolid compacts
Liquisolid technique is one of the methods used to improve the dissolution rate of the poorly water soluble drugs utilizing non volatile liquids. Enhancement of the release of ezetimibe from different liquisolid formulations. Four liquid vehicles were used to prepare the liquid medications with diff...
Saved in:
Published in | Pharmaceutical development and technology Vol. 18; no. 2; p. 417 |
---|---|
Main Authors | , , |
Format | Journal Article |
Language | English |
Published |
England
01.03.2013
|
Subjects | |
Online Access | Get more information |
Cover
Loading…
Abstract | Liquisolid technique is one of the methods used to improve the dissolution rate of the poorly water soluble drugs utilizing non volatile liquids.
Enhancement of the release of ezetimibe from different liquisolid formulations.
Four liquid vehicles were used to prepare the liquid medications with different drug concentrations. The interaction between the drug and the excipients in liquisolid powders were characterized by DSC, X-ray, FTIR and SEM. Furthermore, the powder characteristics were evaluated by Carr's Index and powder wetting time determinations, respectively. All prepared formulations were compressed at different pressures to end with the same constant porosity and the tablets were evaluated by different tests and compared with conventional formula.
No interaction had been detected in all liquisolid formulations as shown in the results of XRD, FTIR, DSC and SEM. In addition to that, all liquisolid compacts had expressed faster dissolution profiles compared with that of conventional formula.
The dissolution rate was affected by the drug concentration, solubility of the drug in the liquid vehicle and type of carrier. In addition, the presence of the liquid vehicle has been found to affect the mechanical properties of the liquisolid formulations. |
---|---|
AbstractList | Liquisolid technique is one of the methods used to improve the dissolution rate of the poorly water soluble drugs utilizing non volatile liquids.
Enhancement of the release of ezetimibe from different liquisolid formulations.
Four liquid vehicles were used to prepare the liquid medications with different drug concentrations. The interaction between the drug and the excipients in liquisolid powders were characterized by DSC, X-ray, FTIR and SEM. Furthermore, the powder characteristics were evaluated by Carr's Index and powder wetting time determinations, respectively. All prepared formulations were compressed at different pressures to end with the same constant porosity and the tablets were evaluated by different tests and compared with conventional formula.
No interaction had been detected in all liquisolid formulations as shown in the results of XRD, FTIR, DSC and SEM. In addition to that, all liquisolid compacts had expressed faster dissolution profiles compared with that of conventional formula.
The dissolution rate was affected by the drug concentration, solubility of the drug in the liquid vehicle and type of carrier. In addition, the presence of the liquid vehicle has been found to affect the mechanical properties of the liquisolid formulations. |
Author | Sheikh Salem, M Khanfar, M Hawari, R |
Author_xml | – sequence: 1 givenname: M surname: Khanfar fullname: Khanfar, M email: mskhanfar@just.edu.jo organization: Department of Pharmaceutical Technology, Faculty of Pharmacy, Jordan University of Science and Technology, Irbid, Jordan. mskhanfar@just.edu.jo – sequence: 2 givenname: M surname: Sheikh Salem fullname: Sheikh Salem, M – sequence: 3 givenname: R surname: Hawari fullname: Hawari, R |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/22530561$$D View this record in MEDLINE/PubMed |
BookMark | eNo1j09LxDAUxIMo7h_9BiL5Al3fS5MmPcriqrDgRQ-eljR90UjbrEl70E9vQT3NwAw_ZlbsdIgDMXaFsCkR6hsEU2qpYCMAxaYyoGp5wpZzpIvaVHrBVjl_AKCpQZ2zhRCqBFXhkr3uYuqnzo4hDtxbN8aUufWe3BiGNz6-E0_Ukc3Eo-f0TWPoQ0Pcp9jzNszFRMPIu_A5hRy70HIX--PMyRfszNsu0-WfrtnL7u55-1Dsn-4ft7f7wkk0YyE1giPpbDU7R61oynl_KVqFKE0DJDx6iVrP47WXrZNSEWhlKkQFxoo1u_7lHqemp_ZwTKG36evw_1H8AGvjVIM |
CitedBy_id | crossref_primary_10_1080_10717544_2016_1250140 crossref_primary_10_1007_s40005_016_0236_1 crossref_primary_10_53879_id_58_01_12717 crossref_primary_10_1016_j_xphs_2022_08_033 crossref_primary_10_53879_id_59_01_12769 crossref_primary_10_1208_s12249_020_01754_5 crossref_primary_10_1016_j_powtec_2018_01_068 crossref_primary_10_1517_17425247_2014_877885 crossref_primary_10_4155_tde_2019_0063 crossref_primary_10_1016_j_ijpharm_2021_121277 crossref_primary_10_4155_tde_2019_0020 crossref_primary_10_3390_pharmaceutics14091787 crossref_primary_10_15171_bi_2017_02 crossref_primary_10_52711_2231_5659_2022_00018 crossref_primary_10_1007_s13346_018_0514_8 crossref_primary_10_52711_2231_5659_2024_00010 crossref_primary_10_1080_01932691_2020_1842211 crossref_primary_10_1007_s40005_015_0225_9 crossref_primary_10_3390_pharmaceutics11120647 |
ContentType | Journal Article |
DBID | CGR CUY CVF ECM EIF NPM |
DOI | 10.3109/10837450.2012.680594 |
DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) |
DatabaseTitleList | MEDLINE |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | no_fulltext_linktorsrc |
Discipline | Pharmacy, Therapeutics, & Pharmacology |
EISSN | 1097-9867 |
ExternalDocumentID | 22530561 |
Genre | Research Support, Non-U.S. Gov't Journal Article |
GroupedDBID | --- 00X 03L 0BK 0R~ 123 29O 36B 4.4 53G 5VS 8V8 AACCU AALIY AALUX AAPUL AAPXX AAQRR ABBKH ABCRQ ABEIZ ABJNI ABLIJ ABLKL ABUPF ABXYU ACENM ACGEJ ACGFS ACLSK ADCVX ADRBQ ADXPE AECIN AEMOZ AENEX AEOZL AFAUU AFKVX AFQCT AFWLO AGAFX AGDLA AGFJD AGRBW AGYJP AIJEM AIRBT AJEBJ AJWEG AJXHO AKBVH AKVCP ALMA_UNASSIGNED_HOLDINGS ALQZU ALYBC AWYRJ BABNJ BLEHA BOHLJ BVLLS CAG CCCUG CGR COF CS3 CUY CVF DEIEU DKSSO DLVIE DTRLO DU5 DZHFC EBD EBO EBR EBS EBU ECM EHE EIF EJD EMB EMK EMOBN EPL F5P HZ~ JFOCU K1G KRBQP KWAYT KYCEM LJTGL M44 M4Z MK0 NPM NUSFT O9- P2P QRXOQ RNANH RVRKI SV3 TBQAZ TERGH TFDNU TFL TFW TH9 UHWXJ V1S ~1N |
ID | FETCH-LOGICAL-c418t-4710ce4ca6471ced2b368032d51148b0e2f1f41770187f4dc445e0758611508a2 |
IngestDate | Thu May 23 23:18:11 EDT 2024 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 2 |
Language | English |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-c418t-4710ce4ca6471ced2b368032d51148b0e2f1f41770187f4dc445e0758611508a2 |
PMID | 22530561 |
ParticipantIDs | pubmed_primary_22530561 |
PublicationCentury | 2000 |
PublicationDate | 2013-03-01 |
PublicationDateYYYYMMDD | 2013-03-01 |
PublicationDate_xml | – month: 03 year: 2013 text: 2013-03-01 day: 01 |
PublicationDecade | 2010 |
PublicationPlace | England |
PublicationPlace_xml | – name: England |
PublicationTitle | Pharmaceutical development and technology |
PublicationTitleAlternate | Pharm Dev Technol |
PublicationYear | 2013 |
SSID | ssj0018905 |
Score | 2.1140091 |
Snippet | Liquisolid technique is one of the methods used to improve the dissolution rate of the poorly water soluble drugs utilizing non volatile liquids.
Enhancement... |
SourceID | pubmed |
SourceType | Index Database |
StartPage | 417 |
SubjectTerms | Azetidines - chemistry Chemistry, Pharmaceutical - methods Drug Compounding - methods Excipients - chemistry Ezetimibe Liquid Crystals - chemistry Porosity Powders - chemistry Solubility Tablets - chemistry |
Title | Formulation factors affecting the release of ezetimibe from different liquisolid compacts |
URI | https://www.ncbi.nlm.nih.gov/pubmed/22530561 |
Volume | 18 |
hasFullText | |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1LT-MwELZ4XLggHsvylg-IC6SbOE7iHBECIRAI7RaJPaHYHqsRtIAIQu2vZxznUQqIXS5RFEeRm-_rdGY63wwhO0KnodQ89EIWgceNZB7CLL0sUakIItAJtwLn84v45IqfXkfXbVapVJcUsqNGH-pKvoMqXkNcrUr2P5BtHooX8BzxxSMijMd_wvgYHc5q_FYzOCcrCzRqEZQdiZK5dD2MoMj7uQQnKaknoxR7d_njc44bzbWrSFeuuVPtsl723mS9dVtl5Kov3-Xmz3rZwLi67XZYcQ_y297eH_w5msjBZi-ZE7v_Hk9A2GEQdQVWB5zR9NPES4Ubq_HeqjbBrTOR3Gk1J0136DqfBugSJjzybdEd68TCtpMZvx0BeOiXcKIhKsOfr1cnGmrXS9NkOhHWKF7YBE_1x5NI_cgpLO2Gfn20Hds_unrERCxS-iTdBTJfBRP0wDFjkUzBYInsVoAN92m3Fdc97dNdetn2KR8uk79j9KEVfWhDH4r0oRV96L2hDX2opQ9t6ENb-tCaPj_I1fFR9_DEqyZteIoHovDQQ_EVcJXFeKZAMxniZw2Zjmy4LH1gJjAIXGJHOBquFecRoLMpYhtQiIytkJnB_QBWCcXbAsBYSKUAnEGccki0tMmy0BifmTXy072ymwfXTuWmfpnrn65skLmWeJtk1uD3F7bQGSzkdgnfKwYTX74 |
link.rule.ids | 786 |
linkProvider | National Library of Medicine |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Formulation+factors+affecting+the+release+of+ezetimibe+from+different+liquisolid+compacts&rft.jtitle=Pharmaceutical+development+and+technology&rft.au=Khanfar%2C+M&rft.au=Sheikh+Salem%2C+M&rft.au=Hawari%2C+R&rft.date=2013-03-01&rft.eissn=1097-9867&rft.volume=18&rft.issue=2&rft.spage=417&rft_id=info:doi/10.3109%2F10837450.2012.680594&rft_id=info%3Apmid%2F22530561&rft_id=info%3Apmid%2F22530561&rft.externalDocID=22530561 |